Tecan Group Ltd. (SIX: TECN)

Quick Facts / Company Snapshot

Metric	Value
Company Name	Tecan Group Ltd.
Stock Exchange & Ticker	SIX Swiss Exchange: TECN
ISIN	CH0012100191
Headquarters	Seestrasse 103, Männedorf, Switzerland
CEO	Monica Manotas
Total Sales (2025)	CHF 882.5 million
Adjusted EBITDA (2025)	CHF 142.1 million
Reported Net Loss (2025)	CHF 110.7 million
Total Assets (2025)	CHF 1,698.1 million
Shareholders’ Equity (2025)	CHF 1,151.5 million
Equity Ratio (2025)	67.8%
Order Entry (2025)	CHF 900.9 million
R&D Spending (2025)	CHF 68.6 million (7.8% of sales)
Total Employees (Year-End 2025)	3,244
Market Capitalization (Year-End 2025)	CHF 1,610.6 million
Adjusted Earnings Per Share (2025)	CHF 6.87
Proposed Dividend Per Share (2025)	CHF 3.00
Operating Cash Flow (2025)	CHF 138.0 million
Net Liquidity Position (2025)	CHF 160.8 million
Number of Shares Outstanding	12,533,970

Company Overview

Tecan Group Ltd. operates as a pioneer and global leader in the field of laboratory automation. The company’s core purpose centers on improving people’s lives and health by empowering customers to scale healthcare innovation globally, spanning from life science research environments to clinical applications. Tecan achieves this by delivering products, services, and solutions that ensure laboratory processes and medical procedures are precise, reproducible, and compliant with rigorous standards.

The company functions primarily through the research, design, development, and assembly of automated instruments, instrument components, sub-modules, software, reagents, and consumables. These products are utilized across various domains, including life science research, applied markets, clinical diagnostics, and the medical devices sector.

Tecan operates under a dual business model. It markets its proprietary products directly to end-users and simultaneously acts as an Original Equipment Manufacturer (OEM) and Contract Development and Manufacturing Organization (CDMO). In its OEM/CDMO capacity, Tecan develops and manufactures instruments and components that partner companies subsequently distribute into research, in-vitro diagnostic, and medical device markets under their own brands.

Business Segments

Tecan’s operational structure is divided into two distinct, customer-oriented business segments: the Partnering Business and the Life Sciences Business.

Partnering Business (OEM Business)

Revenue (2025): CHF 505.4 million
Percentage of Total Revenue: 57.2% (Calculated from CHF 505.4M / CHF 882.5M)

The Partnering Business segment is dedicated to developing and manufacturing OEM instruments and components distributed by partner companies under their respective names. This segment encompasses contract manufacturing services, which involve material management and the assembly of instruments based on customer design inputs. It also includes engineering services without the delivery of instruments, and the sale of customized instruments tailored to specific customer designs.

In 2025, the Partnering Business experienced a 2.0% decrease in sales in local currencies (5.9% in Swiss francs) compared to the previous year. The segment faced headwinds from weak demand for life science instrumentation, which negatively impacted the sales of Cavro OEM components and Paramit CDMO manufacturing services. Conversely, strength in the diagnostics sector drove solid growth for in-vitro diagnostic systems within the Synergence product line. The segment reported a significant EBIT loss of CHF 103.6 million in 2025, primarily driven by a non-cash impairment charge of CHF 139.5 million related to the strategic restructuring of less profitable product lines. Despite this, the adjusted EBITDA margin for the segment increased to 17.7%, supported by a positive product mix and stringent cost controls.

Life Sciences Business (End-Customer Business)

Revenue (2025): CHF 377.1 million
Percentage of Total Revenue: 42.7% (Calculated from CHF 377.1M / CHF 882.5M)

The Life Sciences Business segment supplies automated workflow solutions directly to end-users. These comprehensive solutions comprise laboratory instruments, software packages, application expertise, services, consumables, and spare parts.

Sales in this segment declined by 1.0% in local currencies (5.0% in Swiss francs) in 2025. The Academia & Government sector saw significantly impacted demand due to budget uncertainties and volatile public funding, notably in the US and China. Biopharma sales were slightly below the prior year in local currencies, though order entry improved in the second half of the year. The segment generated an adjusted EBITDA of CHF 63.4 million, reflecting a margin of 16.5%. The segment absorbed the majority of negative impacts from foreign exchange rates and tariffs during the year, and also recognized a CHF 5.3 million asset write-off related to the decision to exit certain activities at Tecan Genomics.

History and Evolution

Tecan was founded in Switzerland in 1980. Over the decades, it has established itself as a pioneer and global leader in laboratory automation. A significant milestone in its evolution as a CDMO was the acquisition of Paramit Corporation and its affiliates in August 2021, which brought advanced manufacturing capabilities and the highly sustainable “Factory in the Forest” facility in Penang, Malaysia, into Tecan’s portfolio.

In recent years, the company has focused on strategic portfolio optimization. In 2025, this included the decision to discontinue dedicated design functions acquired with Paramit in 2021, shifting to leverage Tecan’s existing design and development capabilities to complement its contract manufacturing offerings. The company also consolidated its precision machining operations in Vietnam and divested related capacities in Morgan Hill, USA. On December 1, 2025, Tecan further expanded its capabilities by acquiring WAKO Automation from Fujifilm, integrating advanced scheduling software to enhance its robotic workcell offerings.

Products and Services

Tecan’s offerings are broadly categorized into the sale of products (instruments, consumables, spare parts) and the provision of services (engineering, contract manufacturing, support).

Products (Instruments, Consumables, Software)

Revenue (2025): CHF 724.4 million
Percentage of Total Revenue: 82.1% (Calculated from CHF 724.4M / CHF 882.5M)

The product portfolio includes laboratory automation platforms, analytical benchtop instruments, OEM instrument components, sub-modules, disposable pipette tips, and specialized software.

Fluent™ Automation Workstation: A flagship automation platform featuring ecodesign elements like stand-by modes and highly efficient motor control protocols. It utilizes FluentControl™ software, which was updated in 2025 to include advanced capabilities like spiral pipetting.
Spark™ Reader: An analytical benchtop instrument utilized for various detection applications.
Veya™: Launched in 2025, this system integrates cutting-edge pipetting technology with an intuitive touchscreen interface, guided workflows, and AI-monitored pipetting.
Consumables: A broad portfolio including disposable pipette tips. In 2025, select MCA384 and LiHa tip products achieved ACT® EcoLabel certification.

Services

Revenue (2025): CHF 157.2 million
Percentage of Total Revenue: 17.8% (Calculated from CHF 157.2M / CHF 882.5M)

Services include contract manufacturing, engineering services, and after-sales support. Contract manufacturing involves material management and instrument assembly based on customer designs. Engineering services provide specialized development work for partner companies.

Brand Portfolio

Tecan serves its diverse customer base across the life science research, diagnostics, and medtech spectrum through several distinct brands. While specific revenue breakdowns by individual brand are not explicitly detailed in the provided data beyond the segment level, the core brands represent critical components of the company’s value proposition.

Tecan: The primary brand under which the company markets its direct-to-end-user automated workflow solutions, instruments, and consumables.
Synergence: A product line within the Partnering Business focusing on in-vitro diagnostics systems. In 2025, strength in the diagnostics market drove solid growth for Synergence products.
Cavro: A brand focusing on OEM components. Sales of Cavro components were negatively impacted in 2025 due to overall weak demand for life science instrumentation.
Paramit: Acquired in 2021, Paramit represents Tecan’s Contract Development and Manufacturing Organization (CDMO) services. Paramit CDMO manufacturing services also faced sales headwinds in 2025.

Geographical Presence

Tecan maintains a global sales and service network in over 70 countries, with manufacturing, research, and development sites distributed across Europe, North America, and Asia.

Americas

Revenue (2025): CHF 491.8 million
Percentage of Total Revenue: 55.7% (Calculated from CHF 491.8M / CHF 882.5M)

The Americas represent Tecan’s largest market. Key physical locations include operations in Morrisville, North Carolina (Tecan US Group, Inc.), and multiple facilities in California, including Morgan Hill (Tecan Systems, Inc., Tecan Precision Machining MH, Inc.) and Baldwin Park (Tecan SP, Inc.). In 2025, the company divested precision machining capacities in Morgan Hill. The region accounted for significant physical risk exposure, particularly to extreme heat in California and North Carolina.

Europe, Middle East, and Africa (EMEA)

Revenue (2025): CHF 289.0 million
Percentage of Total Revenue: 32.7% (Calculated from CHF 289.0M / CHF 882.5M)

EMEA is Tecan’s second-largest geographic market. The global headquarters is located in Männedorf, Switzerland. Other significant manufacturing and R&D sites include Grödig, Austria (Tecan Austria GmbH), and facilities in Germany (Crailsheim, Mainz-Kastel, Hamburg). The headquarters in Männedorf operates as a “green building” with solar panels, a living roof, and ISO 14001 certification.

Asia-Pacific (APAC)

Revenue (2025): CHF 101.7 million
Percentage of Total Revenue: 11.5% (Calculated from CHF 101.7M / CHF 882.5M)

The APAC region includes key manufacturing operations such as the “Factory in the Forest” in Penang, Malaysia (Tecan CDMO Solutions PN Sdn. Bhd.), and precision machining operations in Binh Duong Province, Vietnam. The company noted double-digit growth following its direct entry into South Korea.

Tecan Group Ltd. (SIX TECN) Logo

Profit and Loss

The 2025 financial year was marked by subdued end-markets and significant restructuring activities, resulting in a net loss despite resilient operational cash flow.

Metric (CHF 1,000)	2025	2024	Change
Sales	882,480	934,278	-5.5%
Cost of Sales	(571,640)	(613,680)
Gross Profit	310,840	320,598	-3.0%
Gross Profit Margin	35.2%	34.3%
Sales and Marketing Expenses	(113,150)	(110,170)
Research and Development Expenses	(68,582)	(68,387)
General and Administration Expenses	(86,936)	(73,161)
Impairment of Goodwill and PPA Asset	(139,468)	–
Operating Profit / (Loss) (EBIT)	(91,423)	75,573
Adjusted EBITDA	142,100	164,414	-13.6%
Adjusted EBITDA Margin	16.1%	17.6%
Financial Result	(9,833)	2,704
Income Taxes	(9,397)	(10,613)
Profit / (Loss) for the Period	(110,653)	67,664	n.a.
Adjusted Net Profit	86,959	103,119	-15.6%
Basic Earnings Per Share (CHF)	(8.74)	5.30	n.a.
Adjusted Earnings Per Share (CHF)	6.87	8.08	-15.0%

Gross Profit Insights: The gross profit margin increased to 35.2% from 34.3%, driven by positive product mix, price increases, and efficiency improvements, which offset the negative impacts of tariffs, lower sales volumes, and foreign exchange effects.
Operating Expenses: Total operating expenses (excluding cost of sales) rose to CHF 268.7 million (30.4% of sales), primarily due to one-time restructuring costs in G&A and higher performance-related compensation.
Impairment: A massive non-cash impairment charge of CHF 139.5 million was recorded due to the strategic restructuring of less profitable product lines within the Partnering Business.

Balance Sheet

Tecan maintains a solid balance sheet, characterized by a high equity ratio and a strong net liquidity position, despite the impairment charges incurred in 2025.

Metric (CHF 1,000)	31.12.2025	31.12.2024
Cash and Cash Equivalents	176,370	154,193
Other Current Financial Assets	136,960	251,965
Trade Accounts Receivable	126,515	148,561
Inventories	212,572	230,499
Total Current Assets	711,744	856,306
Property, Plant and Equipment	65,908	78,752
Intangible Assets and Goodwill	812,530	1,069,262
Total Non-Current Assets	986,345	1,265,177
Total Assets	1,698,089	2,121,483
Current Financial Liabilities	10,862	266,129
Total Current Liabilities	288,754	531,252
Non-Current Financial Liabilities	207,928	59,952
Total Non-Current Liabilities	257,844	154,900
Total Liabilities	546,598	686,152
Share Capital	1,283	1,283
Treasury Shares	(52,024)	(28,934)
Retained Earnings	978,856	1,111,808
Total Shareholders’ Equity	1,151,491	1,435,331

Liquidity Position: The net liquidity position (cash, cash equivalents, and short-term time deposits, minus bank liabilities, loans, and bonds) improved to CHF 160.8 million at the end of 2025, up from CHF 153.7 million at the end of 2024.
Equity Ratio: The equity ratio slightly increased to 67.8% as of December 31, 2025, demonstrating strong financial stability.

Cash Flow

Cash flow generation remained robust, underscoring the company’s ability to convert operating profits into cash efficiently.

Metric (CHF 1,000)	2025	2024
Cash Inflows from Operating Activities	137,976	148,541
Cash (Out) / Inflows from Investing Activities	76,501	(48,607)
Cash Outflows from Financing Activities	(187,480)	(81,302)
Increase in Cash and Cash Equivalents	22,177	21,228

Cash Conversion: The cash conversion rate improved significantly to 118% of reported EBITDA, up from 100% in 2024.
Financing Activities: Significant outflows in 2025 included the repayment of a CHF 250 million bond, offset partially by net proceeds of CHF 149.9 million from the issuance of a new bond. The company also utilized CHF 33.4 million for the purchase of treasury shares.
Investing Activities: Investing cash flows were positively impacted by the net repayment of CHF 115 million in time deposits (CHF 445 million repaid vs. CHF 330 million invested). Capital expenditure on property, plant, equipment, and intangible assets totaled CHF 35.3 million.

Board of Directors and Leadership Team

Tecan is governed by a Board of Directors responsible for ultimate supervision, and a Management Board to which daily operations are delegated.

Board of Directors

Dr. Lukas Braunschweiler (Chair): Swiss citizen. Elected in 2018. Former CEO of Sonova Holding AG and RUAG Holding AG. He holds a PhD in Physical Chemistry from ETH Zurich and chairs the Nomination and Governance Committee.
Myra Eskes (Member): Dutch citizen. Elected in 2022. Former President Asia Pacific at Smith & Nephew Plc and held various leadership roles at General Electric. She chairs the Compensation Committee.
Matthias Gillner (Member): Swiss/German citizen. Elected in 2023. Former executive at Hilti Group and currently a member of the Hilti Group Board of Directors. He chairs the Audit Committee.
Dr. Christa Kreuzburg (Member): German citizen. Elected in 2013. Extensive background at Bayer AG and Bayer HealthCare, holding various senior R&D and strategic planning roles.
Dr. Daniel R. Marshak (Member): US citizen. Elected in 2018. Former SVP and Chief Scientific Officer at PerkinElmer, Inc., with deep expertise in biochemistry and cell biology.
Dr. Oliver Fetzer (Member): US citizen. Elected in 2011. Former President and CEO of Viridos Inc. and Cerulean Pharma Inc., with an MBA and PhD in Pharmaceutical Sciences.

Note: Dr. Karen Huebscher left the Board in April 2025, and Monica Manotas transitioned from the Board to CEO in August 2025.

Management Board

Monica Manotas (Chief Executive Officer): US/Colombian citizen. Appointed CEO in August 2025. Previously held extensive leadership roles at Thermo Fisher Scientific, including SVP and President.
Tania Micki (Chief Financial Officer): French/Swiss citizen. Joined in 2020 (tenure until end of May 2026). Previous roles include CRO and Group Internal Audit Head at Sulzer AG.
Mukta Acharya (EVP, Head of Life Sciences Business): US citizen. Joined in 2022. Previously served as VP & GM at Thermo Fisher Scientific.
Ulrich Kanter (EVP, Global Head of Operations & IT): German citizen. Joined in 2014. Former General Manager and Head of R&D at Roche Diagnostics in Graz.
Erik Norström (EVP, Head of Corporate Development): Swedish/Swiss citizen. Joined in 2017. Former Corporate VP Strategic Development and M&A at Chr. Hansen a/s.
Ingrid Pürgstaller (Chief People Officer): Italian citizen. Joined in 2011. Elevated to CPO in 2020, responsible for worldwide talent management.
Andreas Wilhelm (EVP, General Counsel and Secretary of the Board): Swiss citizen. Joined in 2004. Attorney-at-law with extensive legal background.
Dr. Wael Yared (EVP, Chief Technology Officer): US citizen. Joined in 2019 (tenure until end of January 2026). Former VP R&D at PerkinElmer Life Sciences & Technology.

Subsidiaries, Associates, Joint Ventures

Tecan operates globally through a network of 100% wholly-owned subsidiaries dedicated to research, production, distribution, and services.

Tecan Schweiz AG: Männedorf, Switzerland. Research, Production, Distribution. Share capital: CHF 5,000,000.
Tecan US Group, Inc.: Morrisville, NC, USA. Services. Share capital: USD 1,500,000. Operates several sub-entities including Tecan US, Inc. (Distribution) and Tecan SP, Inc. (Research, Production, Distribution).
Tecan CDMO Solutions PN Sdn. Bhd.: Penang, Malaysia. Production, Distribution. Share capital: USD 5,178,000.
Tecan Precision Machining VN Company Limited: Binh Duong, Vietnam. Production. Share capital: VND 10,367,000,000.
Tecan Austria GmbH: Grödig, Austria. Research, Production. Share capital: EUR 1,460,000.
Tecan (Shanghai) Laboratory Equipment Co., Ltd.: Shanghai, China. Distribution. Share capital: CNY 3,417,000.
Tecan Japan Co., Ltd.: Kawasaki, Japan. Distribution. Share capital: JPY 125,000,000.
Tecan France S.A.S.U.: Lyon, France. Distribution. Share capital: EUR 2,760,000.

Other Investments (Including Minority / Portfolio Holdings)

Tecan’s financial disclosures indicate limited involvement in minority or portfolio holdings.

Unquoted Equity Investment (FVOCI): As of December 31, 2025, the company held an unquoted equity investment measured at fair value through other comprehensive income valued at CHF 1.0 million. This position resulted from writing off a previous investment to ‘pro memoria’ due to insolvency, and making a new investment of CHF 1.0 million in 2025.
Convertible Bonds (FVTPL): Valued at a nominal ‘pro memoria’ amount of CHF 1,000 at the end of 2025, down from CHF 3.6 million in 2024, as the associated start-up is in the process of liquidation and repayment is not expected.

Specific revenue contributions or ownership percentages for these minor, unquoted financial investments are not explicitly detailed in the provided financial statements.

Physical Properties (Offices, Plants, Factories, etc.)

Tecan owns and leases various physical properties across the globe to support its manufacturing, R&D, and administrative functions. The total net book value of Property, Plant, and Equipment was CHF 65.9 million in 2025, and Right-of-Use Assets (leases) totaled CHF 66.9 million.

Männedorf Headquarters (Switzerland): A purpose-built, ISO 14001 certified “green building” featuring a living roof, solar panels (generating ~10% of electricity needs), LED lighting, and EV charging stations.
Factory in the Forest (Penang, Malaysia): An award-winning, highly sustainable CDMO facility designed to integrate with nature, utilizing a radiant floor cooling system and a newly installed photovoltaic system covering up to 20% of its electricity consumption. It is currently piloting a “Zero Waste to Landfill” program.
US Facilities: Locations include Morrisville, North Carolina, and several sites in California (Morgan Hill, Baldwin Park). In 2025, precision machining operations in Morgan Hill were divested.
European Facilities: Significant sites include operations in Grödig (Austria) and Crailsheim, Mainz-Kastel, and Hamburg (Germany).

Founders and Parent

Founders: Tecan was founded in Switzerland in 1980. The provided report does not disclose detailed profiles of the original founders.
Parent: The ultimate parent company is Tecan Group Ltd., a publicly traded entity on the SIX Swiss Exchange. There is no overarching corporate parent above Tecan Group Ltd.

Investments and Capital Expenditure Plans

Tecan continues to invest heavily in innovation and operational optimization.

R&D Spending: In 2025, gross research and development costs incurred were CHF 76.9 million, resulting in a net R&D expense on the P&L of CHF 68.6 million. This represents a high investment rate of 7.8% of sales, emphasizing the company’s focus on technology leadership.
Capital Expenditures (CAPEX): Cash outflows for the purchase of property, plant, equipment, and intangible assets totaled CHF 35.3 million in 2025.
Strategic Investments: The company is actively investing in digital transformation and AI. The newly formed Digital Innovation & Transformation Office is embedding digital strategies into the R&D roadmap, focusing on connectivity, open digital ecosystems, and responsible AI adoption.

Shareholding Pattern

Tecan’s shares are widely held by institutional investors. As of December 31, 2025, the following entities held more than 3% of Tecan’s shares:

Chase Nominees Ltd., London (UK): 1,546,910 shares (12.3%)
UBS Fund Management (Switzerland) AG, Basel (CH): 1,313,381 shares (10.5%)
Pictet Asset Management SA, Geneva (CH): 642,866 shares (5.1%)
BlackRock Inc., New York (US): 506,845 shares (4.0%)
Norges Bank (the Central Bank of Norway), Oslo (NO): 433,615 shares (3.5%)
Credit Suisse Funds AG, Zürich (CH): 384,926 shares (3.1%)
Israel Englander – Millennium Partners LP, New York (US): 385,204 shares (3.1%)
Swisscanto Fondsleitung AG, Zürich (CH): 383,060 shares (3.1%)

Future Strategy

Tecan has initiated “Rewired,” a comprehensive transformation program designed to future-proof the organization and drive sustainable, profitable growth. The program aims to achieve sales of CHF 1 billion and a 20% adjusted EBITDA margin by 2028. The strategy is built on three pillars:

Portfolio Optimization and Innovation: Focusing R&D on clearly differentiated platforms, accelerating time-to-market for high-impact innovations, and pruning non-aligned offerings (evidenced by the 2025 impairment in the Partnering Business).
Commercial Excellence and Agility: Sharpening the go-to-market model through better customer segmentation, value-based pricing, and strengthening direct presence in high-growth markets like South Korea and India.
Operational Excellence: Driving supply chain efficiency, manufacturing productivity, and optimizing the global footprint for cost competitiveness, including the recent consolidation of machining operations.

Key Strengths

Market Leadership: Recognized as the leading provider in the markets it serves, particularly in liquid handling and laboratory automation.
Diversified Platform: A synergistic dual business model (Life Sciences and Partnering) that spans life sciences research, diagnostics, and medtech, providing multiple revenue streams.
Innovation Engine: Strong commitment to R&D (7.8% of sales) combining fluidics, robotics, software, and emerging digital/AI capabilities.
Financial Resilience: High operating cash flow conversion (118% of EBITDA) and a strong equity ratio (67.8%), allowing for continued investment and shareholder returns despite market downturns.

Key Challenges and Risks

Subdued End-Markets: The company faced continued subdued demand in 2025, driven by funding uncertainties for Academia & Government customers in the US and China, which directly impacted equipment sales.
Geopolitical and Trade Risks: Tariffs (particularly US tariffs) negatively impacted the gross profit margin by 70 basis points, and foreign exchange effects created a 130-basis-point headwind on the EBITDA margin.
Transition Risks (Climate): Potential increases in transportation, raw material, and electricity costs due to the global transition to a low-carbon economy.
Execution Risks: Management acknowledged inconsistent execution in 2025, necessitating the comprehensive “Rewired” transformation program to streamline operations and improve commercial agility.

Conclusion and Strategic Outlook

Tecan Group navigated a highly complex 2025 characterized by geopolitical pressures, trade tariffs, and sluggish capital expenditure environments in key global markets. While these factors, combined with a significant strategic write-down in the Partnering Business, led to a reported net loss, the underlying cash generation of the business remains exceptionally strong. The launch of the “Rewired” transformation program signals a decisive pivot by the new leadership team toward portfolio discipline, operational efficiency, and aggressive commercial execution.

Looking ahead to 2026, Tecan anticipates a gradual recovery in end markets, projecting low single-digit sales growth in local currencies and an adjusted EBITDA margin between 15.5% and 16.5%. By capturing the accelerating demand for scalable, AI- and data-driven automation in drug discovery and diagnostics, Tecan is fundamentally repositioning itself to achieve its ambitious 2028 targets of CHF 1 billion in sales and a 20% adjusted EBITDA margin.

FAQ

What does Tecan do? Tecan is a leading global provider of laboratory automation solutions. They develop and manufacture instruments, software, and consumables used in life science research, clinical diagnostics, and medical device manufacturing.

Why did Tecan report a net loss in 2025? The net loss of CHF 110.7 million was primarily driven by a one-time, non-cash impairment charge of CHF 139.5 million. This charge was related to the strategic restructuring of less profitable product lines within the Partnering Business segment to focus on higher-value growth areas.

What is the “Rewired” program? “Rewired” is a comprehensive transformation program launched by Tecan to future-proof the business. It focuses on portfolio optimization, commercial excellence, and operational efficiency, aiming to achieve CHF 1 billion in sales and a 20% adjusted EBITDA margin by 2028.

How is Tecan addressing sustainability and climate change? Tecan has committed to Science Based Targets (SBTi), aiming for a 42% absolute reduction in Scope 1 and 2 emissions by 2030, and reaching net-zero by 2050. In 2025, the company successfully sourced 100% renewable electricity for its operations.

Who is the CEO of Tecan? Monica Manotas became the Chief Executive Officer of Tecan on August 1, 2025, bringing extensive leadership experience from the life sciences sector.

Where is Tecan headquartered? Tecan’s global headquarters is located in Männedorf, Switzerland.

Official Site: https://www.tecan.com

Source: Content on FirmsWorld.com is based on publicly available corporate filings, regulatory disclosures, annual reports, SEC 10-K filings, investor relations materials, and, where applicable, direct communications with the company.